Alpl-KO
品系全名
C57BL/6JSmo-Alpltm1Smoc
目录号
NM-KO-18058
品系状态
胚胎冻存
基因信息
基因名
Alpl
品系描述
疾病预测
Childhood Hypophosphatasia
Infantile Hypophosphatasia
验证数据
Fig.1 Survival of Alpl-KO mice in postnatal 15 days. (n=24 for the WT C57BL/6 group, n=50 for the HE Alpl-KO group, n=24 for the HO Alpl-KO group). (Data provided by a collaborator)
Continuous supplementation of vitamin B6 in the diet from the pregnancy stage can significantly reduce the mortality rate caused by epilepsy in homozygous individuals.
Abbr. WT, wild type; HE, Heterozygous; HO, Homozygous.
Fig.2 Body weight of Alpl-KO mice.
The body weight of homozygous Alpl-KO mice was markedly lower than that of both WT and heterozygous Alpl-KO mice (n=24 for the WT C57BL/6 group, n=50 for the HE Alpl-KO group, n=24 for the HO Alpl-KO group. Mean ± SEM. Two-way ANOVA , **p < 0.01, ***p < 0.001, ****p < 0.0001). (Data provided by a collaborator)
Abbr. WT, wild type; HE, Heterozygous; HO, Homozygous.
Fig.3 Bone length of Alpl-KO mice.
The result showed a significant reduction of the bone length in homozygous Alpl-KO mice compared with WT C57BL/6 mice at the age of 1.7-2.1 weeks (n=3 in WT C57BL/6 group, n=7 in HO Alpl-KO group. Mean ± SEM. t-test, **p < 0.01, ***p < 0.001, ****p < 0.0001). (Data provided by a collaborator)
Abbr. WT, wild type; HO, Homozygous.
Fig.4 Body length of Alpl-KO mice.
The body length (A) and the body length gain (B) from postnatal days 7 to 14 were both significantly decreased in homozygous Alpl-KO mice compared to WT C57BL/6 mice (n=24 for the WT C57BL/6 group, n=50 for the HE Alpl-KO group, n=20 for the HO Alpl-KO group. Mean ± SEM. Two-way ANOVA for A and One-way ANOVA for B, *p < 0.05, ****p < 0.0001, ns: no significance). (Data provided by a collaborator)
Abbr. WT, wild type; HE, Heterozygous; HO, Homozygous.
你也可能感兴趣
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
查看Workshop：Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
查看Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
查看
